Regulatory News

CMS approves reimbursement for Mitosol

The Centers for Medicare and Medicaid Services has approved reimbursement for the Mitosol kit for ophthalmic use, according to a press release.

Mitosol (mitomycin for solution, Mobius Therapeutics) delivers antifibrotic agents in glaucoma, refractive and corneal surgery. It will be eligible for a reimbursement of 106% of the average sales price, the release said.

The glaucoma indication for Mitosol is active, while the pterygium and refractive indications are currently awaiting approval from the U.S. Food and Drug Administration, according to the release.

The Centers for Medicare and Medicaid Services has approved reimbursement for the Mitosol kit for ophthalmic use, according to a press release.

Mitosol (mitomycin for solution, Mobius Therapeutics) delivers antifibrotic agents in glaucoma, refractive and corneal surgery. It will be eligible for a reimbursement of 106% of the average sales price, the release said.

The glaucoma indication for Mitosol is active, while the pterygium and refractive indications are currently awaiting approval from the U.S. Food and Drug Administration, according to the release.